Akari Therapeutics PLC (NASDAQ:AKTX) shares are surging on Thursday. Investors are reacting to upcoming earnings and recent intellectual property milestones.
Earnings Anticipation Builds
The oncology biotech company will report first-quarter 2026 earnings on May 26. Analysts currently estimate a loss per share of $2.80. Despite the projected loss, sentiment remains high. Akari has beaten EPS estimates in three consecutive quarters.
European Patent Strengthens IP
On Tuesday, the company announced a major European patent grant. This provides composition-of-matter protection for Akari’s proprietary PH1 ADC payload platform. The patent spans over 35 countries, including Germany, France, and the U.K.
CEO Abizer Gaslightwala stated, “This European patent grant further strengthens the foundation of our proprietary payload platform …
This post was originally published here
